PSYCHOCOGNITIVE STATUS OF PATIENTS WITH ARTERIAL HYPERTENSION COMBINED WITH POST-COVID SYNDROME

Objective: To study the psychocognitive status of patients with arterial hypertension (AH) combined with post-COVID syndrome (PCS). Methods: A prospective cohort study involved 134 patients (84 men and 50 women), mean age 62.4±0.6 years, with AH (controlled arterial hypertension, Grade 1-3). The...

Full description

Bibliographic Details
Main Authors: L.A. SHPAGINA, I.S. SHPAGIN, L.D. KHIDIROVA, A.A. VASILENKO
Format: Article
Language:English
Published: Avicenna Tajik State Medical University 2024-03-01
Series:Паёми Сино
Subjects:
Online Access:https://doi.org/10.25005/2074-0581-2024-26-1-10-17
_version_ 1797234929594007552
author L.A. SHPAGINA
I.S. SHPAGIN
L.D. KHIDIROVA
A.A. VASILENKO
author_facet L.A. SHPAGINA
I.S. SHPAGIN
L.D. KHIDIROVA
A.A. VASILENKO
author_sort L.A. SHPAGINA
collection DOAJ
description Objective: To study the psychocognitive status of patients with arterial hypertension (AH) combined with post-COVID syndrome (PCS). Methods: A prospective cohort study involved 134 patients (84 men and 50 women), mean age 62.4±0.6 years, with AH (controlled arterial hypertension, Grade 1-3). The duration of AH was 5.6±0.2 years. Among them 73 patients and a history of COVID-19 infection (confirmed SARS-CoV-2 infection; duration more than 12 weeks) with subsequent development of PCS, while 61 patients did not have a history of COVID-19. Patients with PCS which were diagnosed with depressive syndrome, were further divided into two subgroups depending on agomelatine intake (those who received this medication and those who refused). A general clinical examination and psychodiagnostics were carried out using validated methods, such as HADS and SPMSQ. Statistical analysis was carried out in the RStudio program. Results: Based on the HADS questionnaire, patients with PCS demonstrated a higher rate of depressive syndrome compared to the patients without a history of COVID-19 (41% vs. 12%, p<0.001). Based on the severity of depressive syndrome, the following rates were found in the groups: subclinically expressed depression – in 26% of patients with PCS vs. 12% of patients without COVID-19 (p<0.001), clinically pronounced depression (only in the group of patients with PCS) – in 15% (p=0.007). Additionally, in patients with PCS psychocogniцtive function was assessed using SPMSQ questionnaire; among them those receiving agomelatine showed significantly less frequent and severe psychocognitive dysfunction compared to those who refuse the medication intake (32% vs. 94%, p=0.001). Conclusion: Patients with PCS are characterized by a more severe manifestation of anxiety-depressive syndrome, and the use of agomelatine shows statistically significant effectiveness in this category of patients.
first_indexed 2024-04-24T16:39:52Z
format Article
id doaj.art-cf05532dfe254cf4b647d64e08160df3
institution Directory Open Access Journal
issn 2074-0581
2959-6327
language English
last_indexed 2024-04-24T16:39:52Z
publishDate 2024-03-01
publisher Avicenna Tajik State Medical University
record_format Article
series Паёми Сино
spelling doaj.art-cf05532dfe254cf4b647d64e08160df32024-03-29T10:59:32ZengAvicenna Tajik State Medical UniversityПаёми Сино2074-05812959-63272024-03-01261101710.25005/2074-0581-2024-26-1-10-17PSYCHOCOGNITIVE STATUS OF PATIENTS WITH ARTERIAL HYPERTENSION COMBINED WITH POST-COVID SYNDROMEL.A. SHPAGINA0I.S. SHPAGIN1L.D. KHIDIROVA2A.A. VASILENKO3Novosibirsk State Medical University, Novosibirsk, Russian Federation. City Clinical Hospital № 2, Novosibirsk, Russian FederationNovosibirsk State Medical University, Novosibirsk, Russian Federation. City Clinical Hospital № 2, Novosibirsk, Russian FederationNovosibirsk State Medical University, Novosibirsk, Russian Federation. Novosibirsk Regional Clinical Cardiology Dispensary, Novosibirsk, Russian FederationNovosibirsk State Medical University, Novosibirsk, Russian Federation. City Clinical Hospital № 2, Novosibirsk, Russian FederationObjective: To study the psychocognitive status of patients with arterial hypertension (AH) combined with post-COVID syndrome (PCS). Methods: A prospective cohort study involved 134 patients (84 men and 50 women), mean age 62.4±0.6 years, with AH (controlled arterial hypertension, Grade 1-3). The duration of AH was 5.6±0.2 years. Among them 73 patients and a history of COVID-19 infection (confirmed SARS-CoV-2 infection; duration more than 12 weeks) with subsequent development of PCS, while 61 patients did not have a history of COVID-19. Patients with PCS which were diagnosed with depressive syndrome, were further divided into two subgroups depending on agomelatine intake (those who received this medication and those who refused). A general clinical examination and psychodiagnostics were carried out using validated methods, such as HADS and SPMSQ. Statistical analysis was carried out in the RStudio program. Results: Based on the HADS questionnaire, patients with PCS demonstrated a higher rate of depressive syndrome compared to the patients without a history of COVID-19 (41% vs. 12%, p<0.001). Based on the severity of depressive syndrome, the following rates were found in the groups: subclinically expressed depression – in 26% of patients with PCS vs. 12% of patients without COVID-19 (p<0.001), clinically pronounced depression (only in the group of patients with PCS) – in 15% (p=0.007). Additionally, in patients with PCS psychocogniцtive function was assessed using SPMSQ questionnaire; among them those receiving agomelatine showed significantly less frequent and severe psychocognitive dysfunction compared to those who refuse the medication intake (32% vs. 94%, p=0.001). Conclusion: Patients with PCS are characterized by a more severe manifestation of anxiety-depressive syndrome, and the use of agomelatine shows statistically significant effectiveness in this category of patients.https://doi.org/10.25005/2074-0581-2024-26-1-10-17anxiety-depressive syndromedepressionagomelatinevaldoxanpost-covid syndromecovid-19arterial hypertension.
spellingShingle L.A. SHPAGINA
I.S. SHPAGIN
L.D. KHIDIROVA
A.A. VASILENKO
PSYCHOCOGNITIVE STATUS OF PATIENTS WITH ARTERIAL HYPERTENSION COMBINED WITH POST-COVID SYNDROME
Паёми Сино
anxiety-depressive syndrome
depression
agomelatine
valdoxan
post-covid syndrome
covid-19
arterial hypertension.
title PSYCHOCOGNITIVE STATUS OF PATIENTS WITH ARTERIAL HYPERTENSION COMBINED WITH POST-COVID SYNDROME
title_full PSYCHOCOGNITIVE STATUS OF PATIENTS WITH ARTERIAL HYPERTENSION COMBINED WITH POST-COVID SYNDROME
title_fullStr PSYCHOCOGNITIVE STATUS OF PATIENTS WITH ARTERIAL HYPERTENSION COMBINED WITH POST-COVID SYNDROME
title_full_unstemmed PSYCHOCOGNITIVE STATUS OF PATIENTS WITH ARTERIAL HYPERTENSION COMBINED WITH POST-COVID SYNDROME
title_short PSYCHOCOGNITIVE STATUS OF PATIENTS WITH ARTERIAL HYPERTENSION COMBINED WITH POST-COVID SYNDROME
title_sort psychocognitive status of patients with arterial hypertension combined with post covid syndrome
topic anxiety-depressive syndrome
depression
agomelatine
valdoxan
post-covid syndrome
covid-19
arterial hypertension.
url https://doi.org/10.25005/2074-0581-2024-26-1-10-17
work_keys_str_mv AT lashpagina psychocognitivestatusofpatientswitharterialhypertensioncombinedwithpostcovidsyndrome
AT isshpagin psychocognitivestatusofpatientswitharterialhypertensioncombinedwithpostcovidsyndrome
AT ldkhidirova psychocognitivestatusofpatientswitharterialhypertensioncombinedwithpostcovidsyndrome
AT aavasilenko psychocognitivestatusofpatientswitharterialhypertensioncombinedwithpostcovidsyndrome